Literature DB >> 19845401

Angiotensin AT1 receptor antagonism ameliorates murine retinal proteome changes induced by diabetes.

Ben-Bo Gao1, Joanna A Phipps, Dahlia Bursell, Allen C Clermont, Edward P Feener.   

Abstract

Diabetic retinopathy is the most common microvascular complication caused by diabetes mellitus and is a leading cause of vision loss among working-age adults in developed countries. Understanding the effects of diabetes on the retinal proteome may provide insights into factors and mechanisms responsible for this disease. We have performed a comprehensive proteomic analysis and comparison of retina from C57BL/6 mice with 2 months of streptozotocin-induced diabetes and age-matched nondiabetic control mice. To explore the role of the angiotensin AT1 receptor in the retinal proteome in diabetes, a subgroup of mice were treated with the AT1 antagonist candesartan. We identified 1792 proteins from retinal lysates, of which 65 proteins were differentially changed more than 2-fold in diabetic mice compared with nondiabetic mice. A majority (72%) of these protein changes were normalized by candesartan treatment. Most of the significantly changed proteins were associated with metabolism, oxidative phosphorylation, and apoptotic pathways. An analysis of the proteomics data revealed metabolic and apoptotic abnormalities in the retina from diabetic mice that were ameliorated with candesartan treatment. These results provide insight into the effects of diabetes on the retina and the role of the AT1 receptor in modulating this response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19845401      PMCID: PMC2798584          DOI: 10.1021/pr9006415

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  45 in total

1.  The Gene Ontology (GO) database and informatics resource.

Authors:  M A Harris; J Clark; A Ireland; J Lomax; M Ashburner; R Foulger; K Eilbeck; S Lewis; B Marshall; C Mungall; J Richter; G M Rubin; J A Blake; C Bult; M Dolan; H Drabkin; J T Eppig; D P Hill; L Ni; M Ringwald; R Balakrishnan; J M Cherry; K R Christie; M C Costanzo; S S Dwight; S Engel; D G Fisk; J E Hirschman; E L Hong; R S Nash; A Sethuraman; C L Theesfeld; D Botstein; K Dolinski; B Feierbach; T Berardini; S Mundodi; S Y Rhee; R Apweiler; D Barrell; E Camon; E Dimmer; V Lee; R Chisholm; P Gaudet; W Kibbe; R Kishore; E M Schwarz; P Sternberg; M Gwinn; L Hannick; J Wortman; M Berriman; V Wood; N de la Cruz; P Tonellato; P Jaiswal; T Seigfried; R White
Journal:  Nucleic Acids Res       Date:  2004-01-01       Impact factor: 16.971

2.  AAC-11, a novel cDNA that inhibits apoptosis after growth factor withdrawal.

Authors:  M Tewari; M Yu; B Ross; C Dean; A Giordano; R Rubin
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

3.  Comprehensive analysis of photoreceptor gene expression and the identification of candidate retinal disease genes.

Authors:  S Blackshaw; R E Fraioli; T Furukawa; C L Cepko
Journal:  Cell       Date:  2001-11-30       Impact factor: 41.582

Review 4.  Prospects for angiotensin receptor blockers in diabetic retinopathy.

Authors:  Anne Katrin Sjølie
Journal:  Diabetes Res Clin Pract       Date:  2007-02-23       Impact factor: 5.602

5.  OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28.

Authors:  C Alexander; M Votruba; U E Pesch; D L Thiselton; S Mayer; A Moore; M Rodriguez; U Kellner; B Leo-Kottler; G Auburger; S S Bhattacharya; B Wissinger
Journal:  Nat Genet       Date:  2000-10       Impact factor: 38.330

6.  Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes.

Authors:  R E Gilbert; D J Kelly; A J Cox; J L Wilkinson-Berka; J R Rumble; T Osicka; S Panagiotopoulos; V Lee; E C Hendrich; G Jerums; M E Cooper
Journal:  Diabetologia       Date:  2000-11       Impact factor: 10.122

7.  Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.

Authors:  A J Barber; E Lieth; S A Khin; D A Antonetti; A G Buchanan; T W Gardner
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

8.  Role of the polyol pathway in high glucose-induced apoptosis of retinal pericytes and proliferation of endothelial cells.

Authors:  Yoshihiro Takamura; Takeshi Tomomatsu; Eri Kubo; Syousai Tsuzuki; Yoshio Akagi
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-24       Impact factor: 4.799

Review 9.  Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy.

Authors:  Sohail Ejaz; Irina Chekarova; Ahmed Ejaz; Amara Sohail; Chae Woong Lim
Journal:  Diabetes Obes Metab       Date:  2007-10-15       Impact factor: 6.577

10.  Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain.

Authors:  Jean-Ehrland Ricci; Cristina Muñoz-Pinedo; Patrick Fitzgerald; Béatrice Bailly-Maitre; Guy A Perkins; Nagendra Yadava; Immo E Scheffler; Mark H Ellisman; Douglas R Green
Journal:  Cell       Date:  2004-06-11       Impact factor: 41.582

View more
  14 in total

Review 1.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

2.  Retinal proteomic changes under different ischemic conditions - implication of an epigenetic regulatory mechanism.

Authors:  Cheri Stowell; Lin Wang; Brian Arbogast; Jing-Quan Lan; George A Cioffi; Claude F Burgoyne; An Zhou
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-06-30

3.  CALIBRATING NON-CONVEX PENALIZED REGRESSION IN ULTRA-HIGH DIMENSION.

Authors:  Lan Wang; Yongdai Kim; Runze Li
Journal:  Ann Stat       Date:  2013-10-01       Impact factor: 4.028

4.  Proteomic Analysis of Embryonic and Young Human Vitreous.

Authors:  Kenneth M P Yee; Edward P Feener; Michele Madigan; Nicholas J Jackson; Ben-Bo Gao; Fred N Ross-Cisneros; Jan Provis; Lloyd Paul Aiello; Alfredo A Sadun; J Sebag
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-11       Impact factor: 4.799

5.  Mechanistic dissection of diabetic retinopathy using the protein-metabolite interactome.

Authors:  Ambrose Teru Patrick; Weilue He; Joshua Madu; Srinivas R Sripathi; Seulggie Choi; Kook Lee; Faith Pwaniyibo Samson; Folami L Powell; Manuela Bartoli; Donghyun Jee; Diana R Gutsaeva; Wan Jin Jahng
Journal:  J Diabetes Metab Disord       Date:  2020-06-18

6.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

7.  Multi-modal proteomic analysis of retinal protein expression alterations in a rat model of diabetic retinopathy.

Authors:  Heather D VanGuilder; Georgina V Bixler; Lydia Kutzler; Robert M Brucklacher; Sarah K Bronson; Scot R Kimball; Willard M Freeman
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

8.  Retinal proteome alterations in a mouse model of type 2 diabetes.

Authors:  Alice Ly; Markus F Scheerer; Sven Zukunft; Caroline Muschet; Juliane Merl; Jerzy Adamski; Martin Hrabě de Angelis; Susanne Neschen; Stefanie M Hauck; Marius Ueffing
Journal:  Diabetologia       Date:  2014-01       Impact factor: 10.122

Review 9.  Novel drugs and their targets in the potential treatment of diabetic retinopathy.

Authors:  Mohd Imtiaz Nawaz; Marwan Abouammoh; Haseeb A Khan; Abdullah S Alhomida; Mubarak F Alfaran; Mohammad Shamsul Ola
Journal:  Med Sci Monit       Date:  2013-04-26

Review 10.  Animal models of diabetic retinopathy: summary and comparison.

Authors:  Angela Ka Wai Lai; Amy C Y Lo
Journal:  J Diabetes Res       Date:  2013-10-27       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.